P1168: DURABLE REMISSION AFTER SEQUENTIAL CD19/20 CAR T-CELL “CAKE-ICING” THERAPY OCCURRED IN REFRACTORY/RELAPSED DLBCL

P1168: DURABLE REMISSION AFTER SEQUENTIAL CD19/20 CAR T-CELL “CAKE-ICING” THERAPY OCCURRED IN REFRACTORY/RELAPSED DLBCL

Bibliographic Details
Main Authors:	Peihao Zheng, Fei Xue, Fan Yang, Shaomei Feng, Yuelu Guo, Hui Shi, Guoai Su, Lixia MA, Liu Rui, Biping Deng, Kai Hu, Xiaoyan Ke
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000971568.04478.eb

Similar Items

P1195: A PROSPECTIVE STUDY OF TARGETED SEQUENTIAL IMMUNOTHERAPY. IN PATIENTS WITH RELAPSED REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA.
by: Yuelu Guo, et al.
Published: (2023-08-01)

PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM CHINA
by: Guoai Su, et al.
Published: (2023-08-01)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
by: Vera Rentsch, et al.
Published: (2022-05-01)

Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
by: Zhang J, et al.
Published: (2023-02-01)

Spontaneous Remission and Concomitant Progression in a Patient with DLBCL
by: Eun Ji Han, et al.
Published: (2020-11-01)

Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP–treated DLBCL
by: Antonin Bouroumeau, et al.
Published: (2021-07-01)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
by: Abdulhaq H, et al.
Published: (2023-07-01)

BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
by: Martin Vogel, et al.
Published: (2023-05-01)

P1173: EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B-CELL LYMPHOMA
by: Fan Yang, et al.
Published: (2023-08-01)

PB2101: A PROSPECTIVE INVESTIGATION INTO THE TIMING AND STATUS OF BCMA-CART IN SECONDARY PLASMA CELL LEUKEMIA
by: Yuelu Guo, et al.
Published: (2023-08-01)

PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL
by: Liu Rui, et al.
Published: (2023-08-01)

P1120: NOVEL TARGETED AGENTS IN COMBINATION WITH R-ICE (R-ICE-X) BASED ON GENOTYPING IN RELAPSED/REFRACTORY DLBCL.
by: Shen Yige, et al.
Published: (2023-08-01)

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
by: Roch Houot, et al.
Published: (2022-02-01)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
by: Bogdan Popescu, et al.
Published: (2019-12-01)

P1165: BETALUTIN® IN PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
by: T. Illidge, et al.
Published: (2022-06-01)

P1174: PI3K INHIBITOR LINPERLISIB COMBINED WITH GEMCITABINE AND OXALIPATIN (GEMOX) IN RELAPSED AND/OR REFRACTORY DLBCL: ANALYSIS BASED ON TUMOR BIOLOGY
by: LI Zhi-Ming, et al.
Published: (2023-08-01)

Sequential infusion of two different chimeric antigen receptor T cells: induction of a deep and durable remission
by: Kailin Xu
Published: (2024-01-01)

PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT
by: Andrey Gavrilenko, et al.
Published: (2023-08-01)

P1138: FIVE-YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L-MIND STUDY
by: Johannes Duell, et al.
Published: (2023-08-01)

Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS
by: Gareth P. Gregory, et al.
Published: (2019-04-01)

Remission and Relapse in Alcohol and Substance Addiction
by: Alkin Yilmaz, et al.
Published: (2014-09-01)

PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
by: M. Hamadani, et al.
Published: (2022-06-01)

P1134: BISPECIFIC ANTI-CD20/19 CAR-T – ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY
by: Nirav Shah, et al.
Published: (2023-08-01)

P1168: CHARACTERISTICS PREDICTIVE OF PROGRESSION DURING FRONTLINE TREATMENT IN AGGRESSIVE B-CELL LYMPHOMAS
by: A. Bock, et al.
Published: (2022-06-01)

The Immunology of DLBCL
by: Taishi Takahara, et al.
Published: (2023-01-01)

P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
by: Muhit Ozcan, et al.
Published: (2023-08-01)

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
by: Allison Bock, et al.
Published: (2023-08-01)

S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HAS FAVORABLE SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AND ≥2 PRIOR THERAPIES: PIVOTAL PHASE II EXPANSION RESULTS
by: M. Dickinson, et al.
Published: (2022-06-01)

Exceptional Responder to Immunotherapy: A Rare Case of Post- HSCT DLBCL Relapse Responding to Nivolumab
by: Irappa Madabhavi, et al.
Published: (2019-04-01)

Characteristics and prognosis of rrDLBCL with TP53 mutations and a high‐risk subgroup represented by the co‐mutations of DDX3X‐TP53
by: Fan Gao, et al.
Published: (2023-05-01)

Lack of Durable Remission with Conventional-Dose Total Skin Electron Therapy for the Management of Sezary Syndrome and Multiply Relapsed Mycosis Fungoides
by: Belinda A. Campbell, et al.
Published: (2019-11-01)

CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement
by: Antonia Maria S. Müller, et al.
Published: (2019-09-01)

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 studyResearch in context
by: Radhakrishnan Ramchandren, et al.
Published: (2023-02-01)

Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
by: Tomoaki Ueda, et al.
Published: (2022-01-01)

P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
by: Wojciech Jurczak, et al.
Published: (2023-08-01)

DLBCL Coast to Coast
by: Melania Tesio
Published: (2018-02-01)

Significance of bulky mass and residual tumor—Treated with or without consolidative radiotherapy—To the risk of relapse in DLBCL patients
by: Susanna Tokola, et al.
Published: (2020-03-01)

Effects Of Camptothecin On Pichia Pastoris Strain Smd1168h Expressing Dna Topoisomerase I On Agar Plates
by: Devi Vadiveloo, Sajetra
Published: (2020)

P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY
by: N. L. Bartlett, et al.
Published: (2022-06-01)

The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial
by: Mathias Witzens-Harig, et al.
Published: (2021-10-01)